ReviewFrontiers in microbiology2026
Therapeutic potential of oncolytic viruses in hematopoietic malignancies: from preclinical insights to clinical realities.
Review in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While certain forms of lymphoma-such as classical Hodgkin lymphoma-are classified as curable, with over half of all patients achieving remission following first-line therapy, a significant proportion of patients still suffer from relapsed or refractory disease. Through autologous stem cell transplantation (ASCT) and chimeric antigen receptor (CAR) T-cell therapy can significantly improve survival rates, their widespread clinical utility is constrained by logistical bottlenecks, manufacturing complexities, and high financial burdens. Similarly, antibody-drug conjugates and bispecific antibodies have achieved striking success against hematologic malignancies, but their clinical adoption is often hindered by the requirement for continuous infusion. Consequently, systemically delivered oncolytic viruses engineered to express immunotherapeutic elements have emerged as highly innovative alternatives. This review provides a comprehensive overview of the current landscape and outlines the therapeutic potential of oncolytic virotherapy in the fight against hematopoietic malignancies. We cross-examined a robust dataset of over 100 preclinical investigations to critically assess the therapeutic efficacy and safety profiles of more than ten diverse oncolytic virus platforms developed for blood cancer treatment, alongside multiple early-phase clinical trials that are completed or currently underway. By synthesizing these preclinical and clinical data, we propose three critical development pathways-enhancing target specificity, arming viral vectors, and designing synergistic combination regimens-to accelerate the translation of clinically viable oncolytic viruses for hematologic oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.